12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

PRO053 regulatory update

The European Commission granted Orphan Drug designation for Prosensa's PRO053 to treat Duchenne muscular dystrophy (DMD). The antisense oligoribonucleotides that...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >